Stockscreener 앱 받기
90.78
1.18%
1.06
시장 영업 전:
90.73
-0.05
-0.06%
전일 마감가:
$89.72
열려 있는:
$90.31
하루 거래량:
14.30M
Relative Volume:
2.76
시가총액:
$52.27B
수익:
$6.30B
순이익/손실:
$1.07B
주가수익비율:
49.32
EPS:
1.8406
순현금흐름:
$1.09B
1주 성능:
+3.91%
1개월 성능:
+3.70%
6개월 성능:
+4.53%
1년 성능:
+17.67%
1일 변동 폭
$89.33
$92.46
1주일 범위
$85.31
$92.46
52주 변동 폭
$72.30
$92.46
에드워즈라이프사이언시스 Stock (EW) Company Profile
명칭
Edwards Lifesciences Corp
전화
(949) 250-2500
주소
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
90.78 | 52.27B | 6.30B | 1.07B | 1.09B | 1.8406 |
ABT
Abbott Laboratories
|
94.12 | 163.94B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
332.71 | 127.55B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.98 | 103.66B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.23 | 65.74B | 20.62B | 3.56B | 3.48B | 2.3847 |
에드워즈라이프사이언시스 Stock (EW) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-01 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2026-01-09 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-12-18 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-11-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-10-29 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-10-07 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-07-29 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2025-04-24 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | 업그레이드 | Stifel | Hold → Buy |
| 2025-01-16 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-11 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-09-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-07-31 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-07-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-25 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-07-25 | 다운그레이드 | Truist | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-05-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-05-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-03-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-02-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-11-28 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-07-19 | 개시 | Robert W. Baird | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Overweight |
| 2023-03-29 | 개시 | UBS | Neutral |
| 2023-03-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | 다운그레이드 | Bernstein | Outperform → Underperform |
| 2023-01-30 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-10-28 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-10-26 | 개시 | Mizuho | Buy |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-29 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | 개시 | Truist | Buy |
| 2022-04-06 | 개시 | Wolfe Research | Outperform |
| 2022-03-16 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | 재개 | BofA Securities | Neutral |
| 2022-02-02 | 업그레이드 | UBS | Neutral → Buy |
| 2022-01-27 | 재확인 | Citigroup | Buy |
| 2022-01-27 | 재확인 | Evercore ISI | Outperform |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | Stifel | Buy |
| 2022-01-27 | 재확인 | UBS | Neutral |
| 2021-12-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-12-15 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-12-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | 재확인 | Canaccord Genuity | Buy |
| 2021-07-30 | 재확인 | Deutsche Bank | Hold |
| 2021-07-30 | 재확인 | Jefferies | Buy |
| 2021-07-30 | 재확인 | Morgan Stanley | Overweight |
| 2021-07-30 | 재확인 | Oppenheimer | Outperform |
| 2021-07-30 | 재확인 | Stifel | Buy |
| 2021-07-30 | 재확인 | UBS | Neutral |
| 2021-07-30 | 재확인 | Wells Fargo | Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-04-05 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-11 | 재확인 | Canaccord Genuity | Buy |
| 2020-09-11 | 개시 | Wolfe Research | Underperform |
| 2020-04-28 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-10 | 개시 | Oppenheimer | Outperform |
| 2020-01-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-10-24 | 재확인 | Canaccord Genuity | Buy |
| 2019-09-23 | 개시 | Piper Jaffray | Overweight |
| 2019-07-24 | 재확인 | BofA/Merrill | Buy |
| 2019-03-18 | 재확인 | Canaccord Genuity | Buy |
| 2019-01-18 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | 개시 | Deutsche Bank | Hold |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-16 | 개시 | Barclays | Underweight |
| 2018-10-02 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
모두보기
에드워즈라이프사이언시스 주식(EW)의 최신 뉴스
Edwards Lifesciences presents fresh trial data, shares supported by robust S&P 500 positioning - Ad-hoc-news.de
Edwards Lifesciences Corporation $EW Shares Sold by OLD National Bancorp IN - MarketBeat
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences Reports New Clinical Trial Updates - Orange County Business Journal
Edwards Lifesciences presents trial data at New York conference - Investing.com
Edwards brings fresh valve data to New York, with TAVR study update - Stock Titan
A Look at Edwards Lifesciences Corp (EW) After 3.1% Gain -- GF V - GuruFocus
Edwards Lifesciences stock hits 52-week high at 89.7 USD By Investing.com - Investing.com South Africa
Edwards Lifesciences stock hits 52-week high at 89.7 USD - Investing.com
Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences clears fresh Medicare hurdle, shares consolidate after 52-week high - Ad-hoc-news.de
Edwards Lifesciences Corp (EW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SAPIEN 3 Ultra from Edwards Lifesciences Corp.lower-profile TAVI and refined delivery - AD HOC NEWS
Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors - MarketWatch
Edwards Lifesciences Stocklong-term heart valve strategy in focus - AD HOC NEWS
Why Edwards Lifesciences’ Sapien 3 Ultra Resilia aims for quieter TAVI procedures - AD HOC NEWS
Top Edwards Lifesciences (EW) Competitors 2026 - MarketBeat
Edwards Lifesciences CEO Zovighian sells $45,982 of stock By Investing.com - Investing.com India
Edwards Lifesciences CEO Zovighian sells $45,982 of stock - Investing.com
Edwards Lifesciences Corp (EW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Edwards Lifesciences Corp (EW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Edwards Lifesciences Corp (EW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Edwards Lifesciences (EW) CEO sells 523 shares under Rule 10b5-1 plan - Stock Titan
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Edwards Lifesciences Corp (EW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Edwards Lifesciences stock hits 52-week high at $89.50 By Investing.com - Investing.com Australia
Edwards Lifesciences (EW) Hits 52-Week High on Medicare Coverage Proposal - GuruFocus
Edwards Lifesciences (EW) Sees Gains Following CMS Coverage Prop - GuruFocus
Edwards Lifesciences (EW) Sees 3% Rise Following CMS Coverage An - GuruFocus
Edwards Lifesciences (EW) Sees Positive Coverage Update Boosting Stock Prospects - GuruFocus
Edwards Lifesciences (EW) Gains Analyst Support Amid Coverage Up - GuruFocus
Edwards Lifesciences (EW) Set to Gain from Medicare Coverage Exp - GuruFocus
Edwards Lifesciences Stands Out As US Agency Eyes Broader Access For Heart Valve Device - Benzinga
Edwards Lifesciences jumps as CMS posts proposed TAVR coverage update - Quiver Quantitative
Is Edwards Lifesciences Ready For Its Next Growth Phase? - Kalkine Media
Edwards Lifesciences stock hits 52-week high at $89.50 - Investing.com
Why is Edwards Lifesciences stock climbing today? - Investing.com
Edwards Lifesciences stock jumps on TAVR coverage proposal - Investing.com
Leerink reiterates Edwards Lifesciences stock rating on TAVR policy - Investing.com
Leerink reiterates Edwards Lifesciences stock rating on TAVR policy By Investing.com - Investing.com UK
Edwards Lifesciences Corp. stock rises Monday, still underperforms market - MarketWatch
Edwards Lifesciences Stock (US28176E1082): Valuation Metrics Under the Microscope - AD HOC NEWS
Is Edwards Lifesciences stock underperforming the Nasdaq? - MSN
Sector Gamma AS Acquires 23,422 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Parnassus Investments LLC Acquires 111,843 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Stock Watched As Procedure Recovery Matters - Kalkine Media
Deutsche Bank AG Has $475.59 Million Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
CIBC Asset Management Inc Grows Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors - MarketWatch
Edwards Lifesciences (NYSE:EW) Hits New 1-Year HighTime to Buy? - MarketBeat
에드워즈라이프사이언시스 (EW) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.07%
0.70%
자본화:
|
볼륨(24시간):